文献速递免疫规划传染病防控与疫情报告

口服LacVax® OmpA疫苗诱导小鼠对福氏志贺菌2a的保护性免疫应答

Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
PubMed 文献 · Vaccine · 2019-04-29

本研究在BALB/c小鼠中表征口服重组乳酸乳球菌表达OmpA抗原(LacVax® OmpA)的体液与细胞免疫谱,并用新型人源化小鼠志贺菌病模型评估保护效力。免疫小鼠血清OmpA特异性IgG、粪便sIgA及Th1优势应答(IFN-γ/IL-4比值高)显著升高,攻毒后获得保护,血清IgG、粪便sIgA、IFN-γ和IL-10为保护相关因素。

要点

  • 口服LacVax® OmpA可显著提升血清OmpA特异性IgG与粪便sIgA。
  • 免疫应答呈Th1优势,以IFN-γ/IL-4比值升高为指标。
  • 免疫小鼠对人源化志贺菌病模型攻毒具有保护作用。

核心结论

  • LacVax® OmpA是有前景的志贺菌病预防性候选疫苗。

研究设计与样本

  • 在BALB/c小鼠中表征LacVax® OmpA的体液与细胞免疫谱。
  • 使用新开发的人源化小鼠志贺菌病模型评估保护效力。

主要发现

  • 免疫小鼠血清OmpA特异性IgG、粪便sIgA显著升高。
  • 免疫小鼠呈现Th1优势应答,IFN-γ/IL-4比值高。
  • 免疫动物攻毒后获得保护,免受福氏志贺菌2a ATCC 12022感染。
  • 血清IgG、粪便sIgA、IFN-γ和IL-10为保护的相关因素。

关键数值与推荐

  • OmpA特异性血清IgG、粪便sIgA、IFN-γ和IL-10水平为保护相关因素。

临床怎么用

  • 提示口服食品级乳酸乳球菌递送OmpA抗原可作为志贺菌病黏膜疫苗研发方向。

局限性

  • 保护效力尚需在高等动物中进一步验证以支持未来人体应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Shigellosis is an acute invasive disease of the lower intestine, which afflicts millions of people worldwide with an estimated one million fatalities per annum. Despite of extensive research during the last two decades, a vaccine against multi-drug resistant Shigella is not yet available in the market. To provide a safe, effective and broad-spectrum vaccine against Shigella, we explored food grade bacteria Lactococcus lactis (L. lactis) for the delivery of conserved antigenic protein; Outer membrane protein A (OmpA) to the mucosal sites for effective elicitation of systemic and mucosal immunity. We have previously confirmed the immunogenic potential of recombinant L. lactis expressing OmpA (LacVax® OmpA) in BALB/c mice. In the present study, we have characterized the humoral and cellular immune profile of LacVax® OmpA and assessed its protective efficacy using a newly developed human like murine shigellosis model. The significant increase in OmpA specific serum IgG, fecal sIgA and a Th1 dominant immune response (indicated by high INF-γ/IL-4 ratio) in LacVax® OmpA immunized mice revealed successful activation of humoral and cellular immunity. The LacVax® OmpA immunized animals were also protected from human-like shigellosis when challenged with S. flexneri 2a ATCC 12022. The antigen specific serum IgG, fecal sIgA, INF-γ and IL-10 levels were found to be the significant correlates of protection. Collectively these results suggest that the LacVax® OmpA is a promising prophylactic candidate against shigellosis. However, the protective efficacy of LacVax® OmpA in the higher animals would further strengthen its future application in humans.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yagnik B, Sharma D, Padh H, et al. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model. Vaccine. 2019. PMID: 31047673. doi:10.1016/j.vaccine.2019.04.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。